Navigation Links
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Date:9/21/2007

imulating the body's ability to produce insulin in response to elevated levels of blood sugar, inhibiting the release of a hormone called glucagon following meals, slowing the rate at which nutrients are absorbed into the bloodstream and reducing food intake.

About Diabetes

Diabetes affects more than 20 million in the United States and an estimated 246 million adults worldwide(4,5). Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States and costs approximately $132 billion per year in direct and indirect medical expenses(6).

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen(7).

Important Safety Information for BYETTA(R) (exenatide) injection

BYETTA improves glucose (blood sugar) control in patients with type 2 diabetes who are taking metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems with the stomach or food digestion, or those who have severe kidney disease. Before using BYETTA, patients should tell their healthcare provider if they are pregnant, plan to become pregnant, or are breastfeeding. BYETTA has not been studied in children.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is most common when first starting BYETTA, but decreases over time in most patients. BYETTA may reduce
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... NuVasive, Inc. (Nasdaq: ...oping products for minimally disruptive surgical t...ntment of Michael J. Lambert as Executive Vice Pre...mber 9, 2009. The Company also announced several ...chael will be an excellent complement to the NuVas...
(Date:11/6/2009)...Nov. 6 Philips Respironics applaud...nd Prevention (CDC) to raise awareness about an im...ficiency. The CDC,s release of the first-ever gove... in sleeplessness is a milestone in quantifying th...time educator, industry leader and sleep therapy m...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals,... on Tuesday, November 10, 2009 at 8:30 a.m. EST to...and business outlook for the remainder of 2009. R..., will host the call. Keryx will announce its fin...to be issued prior to the call. ,, In order to ...
Breaking Medicine Technology:NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Concord Coalition Releases Issue Brief on Administrations IMAC Proposal 53399 1Concord Coalition Releases Issue Brief on Administrations IMAC Proposal 53399 2Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 1Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 2Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 3Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 4Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 5Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 6Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 7Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 8Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 9National League of Cities Commends President and Congress on Work Towards Health Care Reform 53390 1National League of Cities Commends President and Congress on Work Towards Health Care Reform 53390 2
...ernational Group, Ltd ("Biosensors", "Company"), (... that a next-generation drug-eluting stent,develop...d efficacy as,compared to Johnson & Johnson,s indu... ("Cypher"), based upon nine-month clinical and an...mark study were presented today at,the 2008 Europe...
...oncern that suicide may be a complication of monte...and Drug Administration (FDA) approved oral,drug t... the treatment of,asthma and seasonal allergy symp...an Lung Association has found no evidence of depre... Lung Association researchers Janet Holbrook, PhD,...
Other Medicine Technology:Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 2Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 3American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 2American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 3
(Date:11/6/2009)...nt and CEO of the National Council on Aging: ,,... National Council on Aging urges the House to pass...3962), which we regard as a historic step toward t...re for Americans of all ages. ,, After a carefu... good deal for America,s seniors. H.R. 3962 would ...
(Date:11/6/2009)...The American Academy of Nursing today inducted sev...tt Williams & Wilkins (LWW) nursing publicatio...er Health, a leading provider of information and b...and institutions in medicine, nursing, allied heal...ed on evidence of significant contributions to nur...
(Date:11/6/2009)...th foods until at least 12 months is ideal, dietit...ews) -- Breast-feeding offers health benefits for ...couraged, says an updated position paper released ...the position of the American Dietetic Association ...rition and health protection for the first 6 month...
(Date:11/6/2009)...olitis, study finds , , FRIDAY, Nov. 6 (...tove ranks alongside auto traffic as a risk factor... is the leading cause of hospitalization in the fi...nfants who had more exposure to wood-burning appli...ces or be hospitalized for bronchiolitis," said Dr...
(Date:11/6/2009)...ic activity on a PET scan after radiation therapy ...good local tumor control, according to a study pre...ty Hospital at the 51st ASTRO Annual Meeting. , ...igher the metabolic activity and tumor size on a P...t is to die from lung cancer. , "PET scanning is...
Breaking Medicine News(10 mins):Health News:NCOA Supports H.R. 3962, the Affordable Health Care for America Act 2Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 2Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 3Health News:Breast-Feeding Benefits Moms and Babies: Report 2Health News:Wood Fires Can Harm the Youngest Lungs 2
...N.J., Jan. 25 At a meeting of its,Board of Direct...dends on,both the Common and Preferred Stock of th...8) per share on the outstanding,shares of Common S... cents ($.50) per share on the,outstanding shares ...
...itzerland, Jan. 25 3.5 million lives could be,sav...e-up of malaria,prevention and treatment measures ...ng to a new report released today at the World Eco..., and,free up 427,000 needed hospital beds over fi...
...chers from the Peninsula Medical School in the Sou...00 from the Juvenile Diabetes Research Foundation,...abetes research, to study a unique collection of p...by Dr Alan Foulis, a pathologist from Glasgow, is ...
...n. 25 OPKO Health, Inc. (Amex: OPK ),today annou...d C.,Pfenniger, Jr. to its Board of Directors. The...Board member David Eichler. Mr. Pfenniger was,appo...r and Rick Pfenniger to OPKO,s Board of,Directors ...
...es Full Year 2007 Revenue of Approximately $154 mi...f $204 Million to $208 Million and R... Jan. 25 NuVasive, Inc. (Nasdaq:,NUVA), a medical...cial results for the full year ended December,31, ...
...LYWOOD, Calif., Jan. 25 IPC The,Hospitalist Compa...ospitalist,services, announced yesterday the initi...on stock at a price to the public of $16.00 per sh...f,common stock. The selling stockholders have also...
Other Medicine News:Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 4Health News:Significant funding for type 1 diabetes research 2Health News:OPKO Health Announces Changes to Board of Directors 2Health News:OPKO Health Announces Changes to Board of Directors 3Health News:NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 2Health News:NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 3Health News:IPC The Hospitalist Company, Inc. Prices Initial Public Offering 2
...ow profile, custom knee brace designed to meet the...top professionals, this sport-specific C.Ti.2 feat...zed,for athletes with large Vastus Medialis Obliqu...re engineered with,a slight degree of flexibility ...
... yet, provides functional support for patients eng...per-sleek, wafer-thin design feels lighter than ai... with muscle expansion and contraction for superio..., ACL, MCL, LCL, PCL, rotary and combined instabil...
Rehab TROM
... to further protect the ACL and enhance the Four P...e Point hinges are designed to react during leg ex...last 35 degrees of extension, in order to reduce e.... The hinge has three adjustment settings to vary ...
Medicine Products: